Anti-Müllerian Hormone (AMH) Assays

Helping fertility patients plan for the family they desire 

We offer a simple test to aid healthcare providers in assessing a woman’s ovarian reserve. The Access AMH immunoassay helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life. Partner with us, the market innovator who developed the first ELISA and launched the first automated AMH assay globally, so you can help fertility patients plan for the family they desire.

This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.

Access AMH advantages over other current AMH immunoassays

  • Increase physician and patient confidence with a recombinant human AMH calibrator that is more stable and accurately mirrors AMH in patient samples for greater immunological recognition of antibodies*
  • Experience a 16 times increase in sensitivity

One test, multiple uses

Diagnostic testing of AMH levels is used in:

  • Fertility assessments. AMH testing has significant advantages over other tests, including increased sensitivity and specificity, and consistency in serum levels throughout the menstrual cycle (see Figure 1)1,2

Figure 1. Mean AMH Values across Menstrual Cycle1

AMH levels can be reliably measured during any day of the menstrual cycle.

  • Reproductive aging evaluations. AMH levels decline earlier than other signs of menopause—such as increasing follicle-stimulating hormone (FSH) levels and irregular menses—and could be used to identify age-related infertility3,4

Access AMH advantages over manual assays

  • Reduce testing costs by 16 percent by using an automated AMH test*
  • Decrease technologist handling time by 80 percent and allow for greater walk-away time through random access capabilities and once-a-month system calibration*
  • Achieve 4 times quicker TAT—40 minutes with an automated assay compared with 170 minutes with ELISA*

Evidence for the Access AMH assay

  • The synthetic Access AMH matrix [simulates analyte-free human serum]…[and] is expected to ensure batch-to-batch consistency and assay performance and minimize detection limitations5
  • The automated assay exhibits high levels of stability and sensitivity and shows correlation with the existing ELISA method and between analyzer platforms6

Discover a full line of reproductive assays to meet your testing needs 

Perform a broad range of reproductive testing services with our comprehensive assay portfolio:

  • AFP (ONTD)
  • AMH
  • DHEA-S
  • hFSH
  • hLH
  • Inhibin A
  • Inhibin B
  • PAPP-A
  • Progesterone
  • Prolactin
  • Sensitive Estradiol
  • SHBG
  • Testosterone
  • Total βhCG (5th IS)
  • Unconjugated Estriol

Access AMH is exclusively available for Beckman Coulter Access and DxI immunoassay analyzers. Access AMH setup is quick and easy.


Access Family of Immunoassay Systems
Assay Protocol File (APF) Download

Please review the APF Web Download Installation Instructions prior to installing the APF on your system.

Note: The APF web download is not available for the UniCel DxC 600i system at this time.


We offer product training courses and guides to give you the skills and knowledge you need to operate your clinical laboratory instruments.

See all product training courses and guides ›

Access AMH brochure front page with woman in lab coat and stethoscope around her neck

Brochure Clinical Utility of Access AMH

Review the latest peer-reviewed analytical and clinical evaluations highlighting the value that Access AMH can bring to your patients.


Fertility Assessment in Your Office Is Possible

Watch these short educational presentations from ESHRE as physicians discuss the value of Access AMH
and discover how you can implement AMH testing in your clinical practice today.


Clinical Utility of Automated AMH Technology

Find out how Access AMH results can support patient fertility counseling from an IVF clinic in the UK.

Presenter: Prof. Roy Homburg, M.B., B.S., FRCOG, Head of Research, Homerton Fertility Centre, Homerton University Hospital, London, UK

Clinical Insights and Interpretation
of AMH

Discover results from the first multicenter Access AMH feasibility study in the U.S. correlating Access AMH to poor ovarian response.

Presenter: Michael Alper, M.D., Boston IVF, Assoc. Clinical Prof. of OBGYN, Harvard Medical School

A Powerful Evaluation
Tool for

Understand the difference in AMH distribution among age groups using data from a multicenter study.

Presenter: Lindsay Sun, M.D., Senior Manager, Medical and Scientific Affairs, Beckman Coulter Diagnostics

1Shin, SS et al. "A Prospective Multi-site Evaluation of the Intra-menstrual Cycle Variability of Anti-Müllerian Hormone (AMH) Using an Automated AMH Immunoassay." Poster presented at: AACC 2015, July 26-30, 2015, Atlanta, GA. 
2Toner, JP and Seifer, DB. "Why We May Abandon Basal Follicle-stimulating Hormone Testing: A Sea Change in Determining Ovarian Reserve Using Anti-Müllerian Hormone." Fertil Steril, vol. 99. 2013, pp. 1825-30. 
3Harlow, SD et al. "Executive Summary of the Stages of Reproductive Aging Workshop +10: Addressing the Unfinished Agenda of Staging Reproductive Aging." Menopause, vol. 19. 2012, pp. 387-395. doi: 10.1097/gme.0b013e31824d8f40. 
4Dewailly D et al. "The Physiology and Clinical Utility of Anti-Müllerian Hormone in Women." Hum Reprod Update, vol. 20. 2014, pp. 370-85. doi: 10.1093/humupd/dmt062. 
5Groome, N. "The Design Features and Performance of a State-of-the-art Fully-automated Anti-Müllerian Hormone Immunoassay for the Beckman Access Family of Immunoassay Systems." Beckman Coulter, Inc., 14 July 2015, Accessed 22 Aug. 2017. 
6Pearson, K et al. "Assessment of the Access AMH Assay as an Automated, High-performance Replacement for the AMH Generation II Manual ELISA." Reprod Biol Endocrol, vol. 14. 2016 doi: 10.1186/s12958-016-0143-3. 

*Data available upon request.
For research use only in the United States. Not available in all countries. Please contact your local Beckman Coulter representative for more information.